Global Psychosis Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Evotec, Merck, Gabather - Research and Markets

Research and Markets has announced the addition of the "Psychosis - Pipeline Review, H1 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

• The report provides a snapshot of the global therapeutic landscape of Psychosis
• The report reviews pipeline therapeutics for Psychosis by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Psychosis therapeutics and enlists all their major and minor projects
• The report assesses Psychosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Psychosis

Companies Mentioned:

• Acadia Pharmaceuticals Inc.
• Addex Therapeutics Ltd
• Evotec AG
• Gabather AB
• Glenmark Pharmaceuticals Ltd.
• Heptares Therapeutics Limited
• Integrative Research Laboratories Sweden AB
• Merck & Co., Inc.
• Newron Pharmaceuticals S.p.A.
• Reviva Pharmaceuticals Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Sunovion Pharmaceuticals Inc.
• Wuhan Docan Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/rhvf3r/psychosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006174/en/